XERS vs. MRUS, KRYS, PTCT, MENS, ARWR, ACLX, PCVX, CRNX, PTGX, and KYMR
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Merus (MRUS), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Vaxcyte (PCVX), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.
Xeris Biopharma vs. Its Competitors
Merus (NASDAQ:MRUS) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
Xeris Biopharma has a net margin of -13.01% compared to Merus' net margin of -685.64%. Xeris Biopharma's return on equity of 0.00% beat Merus' return on equity.
96.1% of Merus shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 3.7% of Merus shares are held by insiders. Comparatively, 4.6% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Merus has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.
Xeris Biopharma has higher revenue and earnings than Merus. Xeris Biopharma is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.
In the previous week, Merus had 16 more articles in the media than Xeris Biopharma. MarketBeat recorded 19 mentions for Merus and 3 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.67 beat Merus' score of 0.17 indicating that Xeris Biopharma is being referred to more favorably in the news media.
Merus presently has a consensus target price of $93.12, indicating a potential downside of 1.36%. Xeris Biopharma has a consensus target price of $7.08, indicating a potential downside of 13.88%. Given Merus' higher possible upside, equities research analysts plainly believe Merus is more favorable than Xeris Biopharma.
Summary
Xeris Biopharma beats Merus on 10 of the 16 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:XERS) was last updated on 10/8/2025 by MarketBeat.com Staff
